The J.P. Morgan Healthcare Conference started off with a flurry of deals that reinvigorated excitement across the biopharma ...
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this ...
We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at ...
A new study illustrates the research journey behind the creation of Monteloeder's latest nootropic formulation Mindrevivetm.
JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating ...
Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
LGBTQ+ seniors are also affected by problematic rhetoric and language that belittles and dehumanizes queer experiences, says ...
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...